MNG250
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.420
- ESTROGEN_RESPONSE_LATE+0.322
- OXIDATIVE_PHOSPHORYLATION+0.283
- KRAS_SIGNALING_DN+0.281
- COAGULATION+0.223
- ESTROGEN_RESPONSE_EARLY+0.220
- BILE_ACID_METABOLISM+0.211
- FATTY_ACID_METABOLISM+0.125
- XENOBIOTIC_METABOLISM+0.078
- MYOGENESIS+0.063
Top 10 suppressed
- MITOTIC_SPINDLE-0.452
- WNT_BETA_CATENIN_SIGNALING-0.428
- G2M_CHECKPOINT-0.386
- INTERFERON_GAMMA_RESPONSE-0.380
- PROTEIN_SECRETION-0.361
- UNFOLDED_PROTEIN_RESPONSE-0.341
- INTERFERON_ALPHA_RESPONSE-0.340
- UV_RESPONSE_DN-0.304
- MYC_TARGETS_V2-0.301
- NOTCH_SIGNALING-0.295
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1052 | — | — | 0.854 |
| 2 | 20090334.LumB | — | B | 0.844 |
| 3 | MNG543 | — | — | 0.842 |
| 4 | SRR1312103 | GTEX | — | 0.840 |
| 5 | TCGA-V7-A7HQ-01A-11R-A33J-07 | — | B | 0.824 |
| 6 | SRR1474333 | GTEX | — | 0.823 |
| 7 | TCGA-GM-A3XG-01A-31R-A24H-07 | — | A | 0.819 |
| 8 | TCGA-UY-A78O-01A-12R-A33J-07 | — | — | 0.819 |
| 9 | MNG764 | — | — | 0.817 |
| 10 | SRR818418 | GTEX | — | 0.816 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.420 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.322 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.283 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.281 | Remibrutinib | — uncovered |
| COAGULATION | 0.223 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.220 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.211 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.125 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.078 | Inavolisib | — uncovered |
| MYOGENESIS | 0.063 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.063 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.051 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.050 | Inavolisib | — uncovered |
| HYPOXIA | 0.045 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.039 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.024 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.004 | Inavolisib | — uncovered |